MAP2K7 and cancer: Since the EGFR-activating mutations reside near the ATP cleft targeted by EGFR-TKI, we thus assessed whether our probe has altered the effects on EGFR activation and the downstream signaling pathways, including PI3K-AKT-mTOR and RAS-RAF-MEK-ERK in several cancer cells.